On-demand webinar – Managing a team and patients during a pandemic

21th November 2020, ParadigMS Foundation and MENACTRIMS offered an enriching e-workshop and keynote – MRI in MS // Management during a pandemic. Here you can review the full recording of the keynote on Managing a team and patients during a pandemic.

ABSTRACT

MANAGEMENT DURING A PANDEMIC

Prof Celia Oreja-Guevara concluded the e-workshop with an interesting keynote about managing a team and your patients during a pandemic.

This workshop was made possible with the support of Merck.

BIOGRAPHY

CELIA OREJA-GUEVARA
Professor Celia Oreja-Guevara is Vice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos, Madrid and Professor of Neurology at the University Complutense, Madrid, Spain. After receiving her MD from the University Complutense, Madrid, Professor OrejaGuevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology, University of Munich, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany),Hospital de Fuenlabrada and at the University Hospital La Paz, both in Madrid. Professor Oreja-Guevara’s research interests centre on clinical and neuroimaging correlations in MS and the use of optical coherence tomography. Neuromyelitis optica (NMO) is among her other therapy areas of interest, and Professor OrejaGuevara is actively involved in the evaluation of new drugs for the treatment of MS and NMO. As an investigator, she has participated in a number of MS clinical trials and currently heads the Neuroimaging Group of the Spanish Neurological Society, and she is a member of the Scientific Committee of the European Academy of Neurology. Currently, Professor Oreja-Guevara is an expert for the Spanish Medicines Agency and for the Scientific Advisory Group on Neurology of the European Medicines Agency